An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
|Articles|May 9, 2012
Jawboning by HHS Doesn't Scare Insurers
Advertisement
The Department of Health and Human Services isn’t that much of a bully, it turns out.
Health insurers flagged by the department for “unreasonable” premium hikes are refusing to back down in the first year of HHS’s new rate review authority.
Read the full story:
Source: Politico
The health reform law gave HHS the power to scrutinize “unreasonable” rate hikes in states that didn’t have robust review programs. But “scrutiny” doesn’t give the department power to actually block the rates from going into effect.
Advertisement
Related to this article
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5